Created at 4:53 p.m. Mar, 16, 2025
Author: Jon_Of_Arc
Related Note: 1477089795846 3
Rationale for change

Question ambiguous on which specific VMAT-2 inhibitor they are referring to.

Tetrabenazine also inhibits VMAT-2 and theorized to inhibit neurotransmitter stores like reserpine.

See FDA package insert for tetrabenazine.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf

Reserpine no longer prescribed in US due to drug discontinuation but supposedly it had VMAT 1 + VMAT 2 properties. Package insert no longer available to compare.

Reserpine was theorized to of deplete neurotransmitter transmission via inhibiting vesicular monamine transporters (name not coined yet) was first noted by Arvid Carlsson 1957. See autobiography 1998 describing his work

https://www.fens.org/wp-content/uploads/2020/11/Carlsson-Arvid.pdf

However papers on the discovery of the VMAT 1-2 in the 1990s do discuss reserpine effect on 1 + 2 but tetrabenazine preferentially inhibiting VMAT 2.

https://pmc.ncbi.nlm.nih.gov/articles/PMC50469/

https://pmc.ncbi.nlm.nih.gov/articles/PMC39426/
Source: Other - FDA package insert + original discovery article

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
Empty field
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Other::Only_Step_1&2_Overlap #AK_Step1_v12::#FirstAid::05_Pharm::02_Autonomic_Drugs::11_Sympathomimetics::*Indirect::Reserpine #AK_Step2_v12::#B&B::10_Neuro::03_Movement_Disorders::02_Movement_Disorders #AK_Step1_v12::#Pixorize::^Missing_image #AK_Step2_v12::#FirstAid::09_Neuro::13_Movement_Disorders::01_Huntington_Disease #AK_Step1_v12::#OME::PreClinical::Biochemistry #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#Physeo::09_Pharm::14_Neuro::15_Tetrabenazine #AK_Step1_v12::#Pixorize::03_Pharmacology::16_Other_Neuro_Pharm::13_Tetrabenazine #AK_Step1_v12::#SketchyPharm::01_Autonomic_Drugs::02_Sympathetic::02_Indirect_Sympathomimetics #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield #AK_Step2_v12::#B&B::12_Pediatrics::03_Other::03_Child_Psychiatry::Extra